Sunesis to Host Analyst & Institutional Investor Meeting on October 19, 2011
October 11 2011 - 7:00AM
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that
the Company will host an analyst and institutional investor meeting
on Wednesday, October 19, 2011, from 5:00 to 6:30 PM Eastern Time
in New York City. The event will include an overview of the acute
myeloid leukemia (AML) treatment landscape and the VALOR trial, a
Phase 3, multinational, randomized, double-blind,
placebo-controlled, pivotal clinical trial of vosaroxin in
combination with cytarabine in first relapsed or refractory AML.
The event will be moderated by Daniel Swisher, Chief Executive
Officer of Sunesis, and will include presentations by, and an in
depth panel discussion with, key opinion leaders in AML, including
VALOR principal investigators. Presentations will be followed by a
question and answer session.
The panel will include:
- Eric Feldman, MD, Chair of the VALOR Steering Committee,
Professor of Medicine and Director of the Leukemia Program and
Hematological Malignancies at Weill Cornell Medical College
- Cyrus Mehta, MD, PhD, President and co-founder of Cytel Inc.,
Adjunct Professor of Biostatistics, Department of Biostatistics,
Harvard School of Public Health. Cytel Inc., a highly regarded
statistical services provider, is working with Sunesis in support
of the VALOR trial.
- Farhad Ravandi, MD, a principal investigator of VALOR,
Professor of Medicine, Department of Leukemia, Division of Cancer
Medicine, The University of Texas MD Anderson Cancer Center
- Robert Stuart, MD, a principal investigator of VALOR and member
of the VALOR Steering Committee, founding director of the Aplastic
Anemia & Myelodysplastic Syndrome Foundation, Director of the
clinical component of the Hollings Cancer Center's Hematological
Malignancies Program and Medical Director of the Clinical Trials
Office at the University of South Carolina
A live webcast of the event will be available on the Sunesis
website at http://ir.sunesis.com. A replay of the webcast will be
archived on the "Calendar of Events" page in the Investors and
Media section of the Sunesis website following the event.
About VALOR
VALOR is a Phase 3, randomized, double-blind,
placebo-controlled, pivotal trial in patients with first relapsed
or refractory AML. The trial is expected to enroll 450 evaluable
patients at approximately 100 leading sites in the U.S., Canada,
Europe, Australia and New Zealand. The VALOR trial is currently
open for enrollment and patients will be randomized one to one to
receive either vosaroxin on days one and four in combination with
cytarabine daily for five days, or placebo in combination with
cytarabine. Additionally, the VALOR trial employs an innovative,
adaptive trial design that allows for a one-time sample size
adjustment by the DSMB at the interim analysis to maintain adequate
power across a broad range of clinically meaningful and
statistically significant survival outcomes. The trial's primary
endpoint is overall survival. For more information on the VALOR
trial, please visit www.valortrial.com.
The VALOR logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=8774
About Vosaroxin
Vosaroxin is a first-in-class anticancer quinolone derivative,
or AQD, a class of compounds that has not been used previously for
the treatment of cancer. Vosaroxin both intercalates DNA and
inhibits topoisomerase II, resulting in replication-dependent,
site-selective DNA damage, G2 arrest and apoptosis.
About Acute Myeloid Leukemia
AML is a rapidly progressing cancer of the blood characterized
by the uncontrolled proliferation of immature blast cells in the
bone marrow. The American Cancer Society estimates there will be
12,950 new cases of AML and approximately 9,050 deaths from AML in
the U.S. in 2011. Additionally, it is estimated that prevalence of
AML is approximately 25,000 in the U.S. AML is generally a disease
of older adults, and the median age of a patient diagnosed with AML
is about 67 years. AML patients with relapsed or refractory disease
and newly diagnosed AML patients over 60 years of age with poor
prognostic risk factors typically die within one year, resulting in
an acute need for new treatment options for these patients.
About Sunesis Pharmaceuticals
Sunesis is a biopharmaceutical company focused on the
development and commercialization of new oncology therapeutics for
the treatment of solid and hematologic cancers. Sunesis has built a
highly experienced cancer drug development organization committed
to advancing its lead product candidate, vosaroxin, in multiple
indications to improve the lives of people with cancer. For
additional information on Sunesis, please visit
www.sunesis.com.
The Sunesis Pharmaceuticals, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=8773
SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals,
Inc.
CONTACT: Investor and Media Inquiries:
David Pitts
Argot Partners
212-600-1902
Eric Bjerkholt
Sunesis Pharmaceuticals Inc.
650-266-3717
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Jul 2023 to Jul 2024